Regulus Therapeutics Inc. (NASDAQ:RGLS) Insider Purchases $95,880.00 in Stock

Regulus Therapeutics Inc. (NASDAQ:RGLS - Get Free Report) insider Preston Klassen acquired 12,000 shares of the firm's stock in a transaction dated Tuesday, June 3rd. The shares were acquired at an average price of $7.99 per share, for a total transaction of $95,880.00. Following the acquisition, the insider now directly owns 48,055 shares of the company's stock, valued at approximately $383,959.45. The trade was a 33.28% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Regulus Therapeutics Stock Performance

Shares of NASDAQ:RGLS traded up $0.12 during mid-day trading on Friday, hitting $8.22. 2,775,764 shares of the company traded hands, compared to its average volume of 929,980. The firm has a market cap of $569.10 million, a P/E ratio of -7.68 and a beta of 0.35. Regulus Therapeutics Inc. has a 52-week low of $0.83 and a 52-week high of $8.28. The firm's 50 day simple moving average is $5.36 and its 200 day simple moving average is $2.77.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.14. Equities research analysts expect that Regulus Therapeutics Inc. will post -0.88 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently commented on RGLS. Jones Trading restated a "hold" rating and issued a $7.00 price objective (down from $8.00) on shares of Regulus Therapeutics in a report on Wednesday, April 30th. Leerink Partnrs lowered shares of Regulus Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday, April 30th. Wells Fargo & Company reaffirmed an "equal weight" rating and set a $9.00 price target on shares of Regulus Therapeutics in a research report on Thursday, May 1st. Wall Street Zen began coverage on shares of Regulus Therapeutics in a research report on Sunday, May 18th. They issued a "sell" rating for the company. Finally, Leerink Partners reissued a "market perform" rating and issued a $7.00 target price on shares of Regulus Therapeutics in a research note on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $8.50.

Institutional Trading of Regulus Therapeutics

Several large investors have recently modified their holdings of the business. Federated Hermes Inc. grew its stake in shares of Regulus Therapeutics by 23.1% during the first quarter. Federated Hermes Inc. now owns 15,819,863 shares of the biopharmaceutical company's stock valued at $27,685,000 after acquiring an additional 2,967,209 shares in the last quarter. Octagon Capital Advisors LP grew its stake in shares of Regulus Therapeutics by 13.7% during the fourth quarter. Octagon Capital Advisors LP now owns 4,848,802 shares of the biopharmaceutical company's stock valued at $7,661,000 after acquiring an additional 585,101 shares in the last quarter. Baker BROS. Advisors LP acquired a new stake in shares of Regulus Therapeutics during the first quarter valued at about $4,715,000. Millennium Management LLC grew its stake in shares of Regulus Therapeutics by 69.7% during the fourth quarter. Millennium Management LLC now owns 2,192,158 shares of the biopharmaceutical company's stock valued at $3,464,000 after acquiring an additional 900,743 shares in the last quarter. Finally, Driehaus Capital Management LLC acquired a new stake in shares of Regulus Therapeutics during the first quarter valued at about $1,677,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

Regulus Therapeutics Company Profile

Regulus Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RGLS8429, an anti-miR next generation oligonucleotide targeting miR-17, which is in Phase 1b clinical trial for the treatment of autosomal dominant polycystic kidney disease.